Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from OncoCyte Corporation.

Advances in™ Diagnostic Testing: Assessing Your Patient's Risk of Recurrence to Inform Treatment Decisions in Early-Stage NSCLC

Release Date: February 28, 2020
Expiration Date: February 28, 2021
Media: Internet - based

Activity Overview

Even with recent revisions in non-small cell lung cancer (NSCLC) staging, limitations still remain in the ability to differentiate early-stage, high-risk patients likely to undergo postoperative recurrence from low-risk patients likely to be cured by surgery. The 5-year overall survival among patients with early-stage NSCLC who have undergone surgery continues to stay as low as 55% to 60%, demonstrating a clear need to improve patient selection for adjuvant therapy. In this activity, expert video interviews will help you place into context the advances and research on improving prediction of recurrence and identifying patients most likely to benefit from adjuvant therapy. Techniques and applications for molecular risk stratification will be discussed, as well as data regarding retrospective and prospective trials assessing the impact of molecular risk stratification on outcomes for patients with NSCLC.

Click here to continue the conversation with the expert faculty on an online discussion board. The conversation continues with experts providing guidance on risk-assessment strategies for treatment of NSCLC and answers to real-world issues brought up by participants for the benefit of all HCPs who treat or manage patients with early-stage non-small cell lung cancer.

Click Here to ask Dr. Gandara questions


Acknowledgement of Commercial Support

This activity is supported by an educational grant from OncoCyte Corporation.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review video files/content until you finish the presentation.
  • At the end of the activity, “Educational Content/Videos” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Target Audience

This educational initiative is directed toward medical oncologists, surgical oncologists, thoracic surgeons, pathologists, and other healthcare professionals who treat patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, fellows, and other healthcare professionals interested in the treatment of lung cancer are also invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Outline the staging and risk-assessment strategy for NSCLC that guides postoperative treatment strategies
  • Assess outcomes and survival rates in patients with early-stage NSCLC in the context of current treatment paradigms
  • Evaluate emerging data regarding molecular strategies to risk-stratify patients with early-stage NSCLC
  • Apply evolving risk-stratification data to clinical scenarios for patients with NSCLC

Faculty, Staff, and Planners’ Disclosures


David R. Gandara
David R. Gandara, MD
Professor of Medicine Emeritus
Director, Thoracic Oncology
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosures: Consultant: Amgen, AstraZeneca, Celgene, CellMax Life, FujiFilm, Guardant Health, Inviata, IO Biotech, Lilly, Merck, OncoCyte, Pfizer, Roche-Genentech, Samsung Bioepis; Research Grants: Bristol-Myers Squibb, Merck, Novartis, Roche-Genentech.

Johannes R. Kratz
Johannes R. Kratz, MD
Assistant Professor of Surgery, Department of Surgery
Division of Cardiothoracic Surgery
University of California, San Francisco
San Francisco, CA

Disclosures: Consulting relationship with and receiving personal fees and nonfinancial support from Razor Genomics Inc, the company that established a Clinical Laboratory Improvement Amendments–certified laboratory and developed the molecular assay based on University of California, San Francisco technology, and being inventors of related technology owned by the University of California, for which the University submitted patent applications that have been licensed to Razor Genomics Inc. Patent to the Prognostic Assay For Early-Stage Lung Cancer issued and with royalties paid.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By